Breast Cancer Clinical Trial
All-extremity Exercise During Breast Cancer Chemotherapy
Summary
Currently, there are 3.5 million breast cancer survivors in the United States and this number is expected to increase dramatically. The proposed research will examine whether a novel exercise intervention for breast cancer patients who are undergoing chemotherapy protects against cardiovascular dysfunction. Findings may have implications for cardiovascular disease prevention in this population.
Eligibility Criteria
Inclusion Criteria:
Active diagnosis of primary invasive non-metastatic breast cancer, stages I-III
Female
18 to 85 years of age
Scheduled to initiate neoadjuvant or adjuvant chemotherapy (anthracycline, alkylating agent and/or taxane)
Absence of contraindications to exercise
Study clinician approval
Able to give consent
Informed consent obtained from the subject and documentation of subject agreement to comply with study-related process
Exclusion Criteria:
Do not meet inclusion criteria
Receiving targeted therapies (CDK4/6 or PARP inhibitors)
Receiving radiation therapy concurrent with chemotherapy
Lymphedema stage ≥ 2 prior to study enrollment
Any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
Current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
Current participation in aerobic exercise training (≥150 min/week of moderate-intensity aerobic exercise)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Gainesville Florida, 32611, United States More Info
How clear is this clinincal trial information?